title: Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors.
abstract: BACKGROUND
  Currently available treatments for benign prostatic hyperplasia (BPH) and localized prostate cancer are generally effective but are often attended by serious side effects that impact on the quality of life. In particular, most current therapies are non-specific, with surgery, radiation, and chemical ablation having the potential to cause damage to surrounding tissue. Here, we demonstrate the effectiveness of a prostate-specific, locally delivered gene therapy for the targeted killing of prostate cells.
  
  
  METHODS
  Using a degradable, poly(beta-amino ester) polymer, poly(butane diol diacrylate co amino pentanol) (C32), we developed a nanoparticulate system to deliver a diphtheria toxin suicide gene (DT-A) driven by a prostate specific promoter to cells. These C32/DT-A nanoparticles were directly injected to the normal prostate and to prostate tumors in mice.
  
  
  RESULTS
  Nearly 50% of normal prostates showed a significant reduction in size, attributable to cellular apoptosis, whereas injection with naked DT-A-encoding DNA had little effect. Significant apoptosis was also observed in C32/DT-A injected prostate tumors. Importantly, no damage to surrounding tissue was observed.
  
  
  CONCLUSIONS
  These results suggest that local delivery of poly(beta-amino ester) polymer/ DT-A nanoparticles may have application in the treatment of BPH and prostate cancer.
authors.affiliation: Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA.
authors.forename: Weidan
authors.initials: W
authors.lastname: Peng
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Anderson
authors.forename: Yunhua
authors.initials: Y
authors.lastname: Bao
authors.forename: Robert F
authors.initials: RF
authors.lastname: Padera
authors.forename: Robert
authors.initials: R
authors.lastname: Langer
authors.forename: Janet A
authors.initials: JA
authors.lastname: Sawicki
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D004247:DNA / Q000008:administration & dosage / Q000235:genetics; D004167:Diphtheria Toxin / Q000235:genetics*; D004952:Esters / Q000008:administration & dosage; D015316:Genetic Therapy / Q000379:methods*; D020287:In Situ Nick-End Labeling; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D053758:Nanoparticles / Q000008:administration & dosage*; D010446:Peptide Fragments / Q000235:genetics*; D010957:Plasmids / Q000235:genetics; D011108:Polymers / Q000008:administration & dosage; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000235:genetics*; D011470:Prostatic Hyperplasia / Q000235:genetics / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000628:therapy*; D018709:Statistics, Nonparametric
chemical_list: D004167:Diphtheria Toxin; D004952:Esters; D010446:Peptide Fragments; D011108:Polymers; C029795:diphtheria toxin fragment A; C507253:poly(beta-amino ester); D004247:DNA; D017430:Prostate-Specific Antigen